Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Bertilsson

Showing results (221-230 of 263) with videos related to

Pageof 27
Sort By:
European Journal of Clinical Pharmacology|February 24, 2001
CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patientsM G Scordo, E Spina, P Romeo, et al.
Therapeutic Drug Monitoring|August 15, 2000
Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urineJ A Carrillo, M Christensen, S I Ramos, et al.
Clinical Pharmacology and Therapeutics|July 30, 2010
Clinically significant CYP2C inhibition by noscapine but not by glucosamineS Rosenborg, M Stenberg, S Otto, et al.
Clinical Pharmacology and Therapeutics|July 14, 2001
Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot studyS Härtter, C Ursing, S Morita, et al.
Clinical Pharmacology and Therapeutics|June 21, 2012
UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systemsT Haslemo, I Loryan, N Ueda, et al.
Pharmacogenetics|June 1, 1995
Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjectsM L Dahl, Q Y Yue, H K Roh, et al.
European Journal of Clinical Pharmacology|January 17, 2002
Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patientsH K Roh, C E Kim, W G Chung, et al.
Clinical Pharmacology and Therapeutics|April 1, 1996
The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixolM Jerling, M L Dahl, A Aberg-Wistedt, et al.
Clinical Pharmacology and Therapeutics|November 3, 1998
Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypesQ Y Yue, Z H Zhong, G Tybring, et al.
Pharmacogenetics|December 1, 1992
Genetic polymorphism of cytochromes P450: interethnic differences and relationship to incidence of lung cancerM Ingelman-Sundberg, I Johansson, I Persson, et al.
Pageof 27

Showing results (221-230 of 263) with videos related to

Sort By:
Pageof 27
European Journal of Clinical Pharmacology|February 24, 2001
CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patientsM G Scordo, E Spina, P Romeo, et al.
Therapeutic Drug Monitoring|August 15, 2000
Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urineJ A Carrillo, M Christensen, S I Ramos, et al.
Clinical Pharmacology and Therapeutics|July 30, 2010
Clinically significant CYP2C inhibition by noscapine but not by glucosamineS Rosenborg, M Stenberg, S Otto, et al.
Clinical Pharmacology and Therapeutics|July 14, 2001
Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot studyS Härtter, C Ursing, S Morita, et al.
Clinical Pharmacology and Therapeutics|June 21, 2012
UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systemsT Haslemo, I Loryan, N Ueda, et al.
Pharmacogenetics|June 1, 1995
Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjectsM L Dahl, Q Y Yue, H K Roh, et al.
European Journal of Clinical Pharmacology|January 17, 2002
Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patientsH K Roh, C E Kim, W G Chung, et al.
Clinical Pharmacology and Therapeutics|April 1, 1996
The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixolM Jerling, M L Dahl, A Aberg-Wistedt, et al.
Clinical Pharmacology and Therapeutics|November 3, 1998
Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypesQ Y Yue, Z H Zhong, G Tybring, et al.
Pharmacogenetics|December 1, 1992
Genetic polymorphism of cytochromes P450: interethnic differences and relationship to incidence of lung cancerM Ingelman-Sundberg, I Johansson, I Persson, et al.
Pageof 27